New hope for bladder cancer patients who Can't take chemo?

NCT ID NCT03459846

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial is testing whether combining two drugs, durvalumab (an immunotherapy) and olaparib (a targeted therapy), can help people with advanced bladder cancer who are not healthy enough for standard platinum chemotherapy. About 154 participants will receive either the drug combo or a placebo. The study aims to see if the combination slows cancer growth and improves survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

durvalumab and olaparib

What this could lead to

If successful, this combination could offer a new first-line treatment option for advanced bladder cancer patients who cannot tolerate standard chemotherapy.

What could go wrong

This is a Phase 2 trial with only 154 participants, so results are preliminary. The combination may not improve survival and could cause side effects like fatigue, nausea, or immune-related reactions.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bladder transitional cell carcinoma urinary bladder neoplasm Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

URINARY BLADDER NEOPLASMS

Contacts and locations

Show contact details

Locations

Research Site

Birmingham, Alabama, 35294, United States
Research Site

Goodyear, Arizona, 85338, United States
Research Site

Fort Myers, Florida, 33901, United States
Research Site

St. Petersburg, Florida, 33705, United States
Research Site

Tampa, Florida, 33612, United States
Research Site

Louisville, Kentucky, 40202, United States
Research Site

New Hyde Park, New York, 11042, United States
Research Site

New York, New York, 10065, United States
Research Site

The Bronx, New York, 10461, United States
Research Site

Philadelphia, Pennsylvania, 19124, United States
Research Site

Nashville, Tennessee, 37232, United States
Research Site

Tacoma, Washington, 98405, United States
Research Site

Greater Sudbury, Ontario, P3E 5J1, Canada
Research Site

Hamilton, Ontario, L8V 5C2, Canada
Research Site

Newmarket, Ontario, L3Y 2P9, Canada
Research Site

Toronto, Ontario, M5G 2M9, Canada
Research Site

Montreal, Quebec, H3T 1E2, Canada
Research Site

Moscow, 105077, Russia
Research Site

Moscow, 125367, Russia
Research Site

Novosibirsk, 630108, Russia
Research Site

Omsk, 644013, Russia
Research Site

Saint Petersburg, 194354, Russia
Research Site

Saint Petersburg, 195271, Russia
Research Site

Saint Petersburg, 199178, Russia
Research Site

Incheon, 21565, South Korea
Research Site

Seoul, 02841, South Korea
Research Site

Seoul, 03722, South Korea
Research Site

Seoul, 05505, South Korea
Research Site

Seoul, 6351, South Korea
Research Site

Barcelona, 08036, Spain
Research Site

Madrid, 08035, Spain
Research Site

Madrid, 28041, Spain
Research Site

Málaga, 29010, Spain
Research Site

Santiago de Compostela, 15706, Spain
Research Site

Kaohsiung City, 807, Taiwan
Research Site

Kaohsiung City, Taiwan
Research Site

Taichung, 40705, Taiwan
Research Site

Tainan, 704, Taiwan
Research Site

Taipei, 10002, Taiwan
Research Site

Taipei, 104, Taiwan
Research Site

Taipei, 112, Taiwan
Research Site

Taoyuan City, 333, Taiwan
Research Site

Hanoi, 100000, Vietnam
Research Site

Ho Chi Minh City, 700000, Vietnam